Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Double-Blind, Placebo-Controlled, Multicenter Acute Study of Clinical Effectiveness of Nesiritide in Subjects With Decompensated Heart Failure (ASCEND-HF)

Next Previous
Trial Profile

Double-Blind, Placebo-Controlled, Multicenter Acute Study of Clinical Effectiveness of Nesiritide in Subjects With Decompensated Heart Failure (ASCEND-HF)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Feb 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nesiritide (Primary)
  • Indications Acute heart failure; Decompensated heart failure
  • Focus Registrational; Therapeutic Use
  • Acronyms ASCEND-HF
  • Sponsors Janssen-Cilag; Scios

    • Most Recent Events

    • 01 Jan 2023 Results (n=5741) comparing NYHA Class and patient-reported health outcomes in cohort of patients hospitalized for heart failure, majority of patients exhibited discordance between clinician-reported NYHA class published in the Circulation: Heart Failure
    • 01 Dec 2022 Results of an analysis comparing patient-reported and clinical outcomes between patients hospitalized with HFrEF vs HFpEF published in the Journal of Cardiac Failure
    • 07 Nov 2022 Results (n=5741) Comparing Patient Reported Outcomes and New York Heart Association Class Among Patients Hospitalized for Heart Failure presented at the American Heart Association Scientific Sessions 2022
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top